
Novartis’ Fabhalta Gets a Thumbs-Up from the FDA: A Humorous and Quirky Look at the Label Expansion Approval!
A New Hope for Ultra-Rare Kidney Disease: NVS’ Fabhalta Gets Recommended for Approval In a recent turn of events, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for NVS’ Fabhalta, a potential treatment for adults suffering from C3 glomerulopathy. This ultra-rare, progressive kidney disease has left the…